Regulus Therapeutics expands advisory board


Regulus Therapeutics Inc., a La Jolla-based biopharmaceutical company working on medicines targeting microRNAs, has added Gregory Hannon, Ph.D., to its Scientific Advisory Board. Hannon’s work has involved the molecular identification and characterization of the microRNA pathway.

Hannon is a professor and Howard Hughes Medical Institute Investigator at Cold Spring Harbor Laboratory.

“We are delighted to add Greg to our SAB as he brings new insights to the already outstanding group of scientific advisors aiding us in the understanding of microRNA biology,” said Neil W. Gibson, Ph.D., chief scientific officer of Regulus.